BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax (ABT-199) is a BH3 mimetic and a specific inhibitor to BCL2 that is currently approved for treatment of CLL by the U.S. Food and Drug Administration (FDA) for use in CLL patients who have received prior therapy [60, 61].